Pediatric drugs eligible for PE exemptions from January
By Kim, Jung-Ju | translator Alice Kang
22.11.30 06:00:42
가나다라
0
Chang-Hyun Oh, Director of the Pharmaceutical Benefits Division, says drugs used for adults excluded from priority
NHIS’s negotiation guidelines are being revised... the ‘small number’ standard anticipated to be flexibly applied during the DREC review
Guideline to be comprehensively revised in December, including expanding drug pricing reference countries and expedited listing for severe disease treatments
▲Chang-Hyun Oh, Director of MOHW
The government expects the ‘Measures to Improve Patient Access and Reinforce Reimbursement Management for High-Priced Severe Disease Treatments’ that gained industry attention for increasing thescope of use of the pharmacoeconomic evaluation exemption system (PE exemption system) will be applied to drugs that apply for reimbursement in January.
In other words, the government plans to confirm and apply final revisions in December. The revisions to the Health Insurance Review and Assessment Service’s guidelines are currently complete and are being reflected in the National Health Insurance Service’s detailed standards for negotiations (negotiation guidelines). After the process is complete,
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)